| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8679468 | Thrombosis Research | 2018 | 6 Pages |
Abstract
In this review, we discuss the role of podoplanin in promoting cancer-associated VTE. Since podoplanin is associated with VTE risk in brain tumor patients, it could be a useful biomarker to identify patients at very high VTE risk. Those patients may benefit from primary thromboprophylaxis. In addition, the podoplanin-CLEC-2 axis might serve as an attractive target for new therapies against cancer-associated VTE.
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Pegah Mir Seyed Nazari, Julia Riedl, Ingrid Pabinger, Cihan Ay,